The Anosh Inc Foundation is a nonprofit organization based in Chicago, focused on enhancing lives through programs in ...

ALK ( ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EUR neffy® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Net Profit Achieved: Q2 2025 marked Hapbee’s first profitable quarter in company history, with net income of $17,988, compared to a net loss of $178,984 in Q1 2025 and a loss of $1.86 million in Q2 ...

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement ...

Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...

EURneffy is the trade name for neffy® (epinephrine nasal spray) in the United Kingdom. About neffy® neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in ...

Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan, and was granted as an inducement material to each employee’s employment with Aardvark in ...

On 14 July 2025, Fagron received a notification that the shareholding of Alychlo NV, crossed the disclosure threshold of 3% downwards as the result of the disposal of voting securities or voting ...

Mirdametinib is marketed under the brand name EZMEKLY ® in the European Union and is conditionally approved by the European Commission (EC) for the treatment of symptomatic, inoperable plexiform ...

The live webcast will be available on Connect’s website in the Investors section under Presentations, Events & News at investors.connectbiopharm.com. An archived replay will be available for ...

The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on July 22, 2025 under the Company’s existing trading symbol “GBIO” with the new CUSIP number ...